Submit Comments by 11/22/2024
Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment on a draft guidance before it begins work on the final version of the guidance, submit either online or written comments on the draft guidance before the close date.
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document’s docket number: FDA-2019-D-3805
Docket Number: FDA-2019-D-3805 Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research
This guidance provides information regarding how basic safety and essential performance standards are incorporated into the Accreditation Scheme for Conformity Assessment Program (hereafter referred to as the ASCA Program). The ASCA Program is described in FDA’s guidance, The Accreditation Scheme for Conformity Assessment (ASCA) Program.
-
Content current as of:
09/20/2024
-
Regulated Product(s)
Topic(s)
